First in class, oral androgen receptor signaling inhibitor (ARSI) candidate in Phase 3 development for advanced prostate cancer
Based on the mechanism of MDV3100, we believe it could be useful in a broad spectrum of prostate cancer disease states, with the first step to develop it for patients with the most advanced disease and in greatest need.
More...